Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732783 | PMC |
| http://dx.doi.org/10.1002/hon.70033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton's Tyrosine Kinase Inhibitors: A Comprehensive Overview.
Hematol Oncol Clin North Am
July 2025
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Continuous treatment with Bruton's tyrosine kinase (BTK) inhibitors is well established for chronic lymphocytic leukemia in the frontline setting. Long-term data shows near-normal life expectancy for patients who are treated with ibrutinib. Second-generation BTK inhibitors have improved tolerability compared to ibrutinib and continue to show long-term durable remissions.
View Article and Find Full Text PDFAcalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
J Clin Oncol
July 2025
Medizinische Klinik III, Klinikum der Universitaet Munchen, Muenchen, Germany.
Purpose: The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely because of toxicity. Acalabrutinib was shown to be efficacious and less toxic than ibrutinib in a head-to-head trial in chronic lymphocytic leukemia and therefore might lead to better outcomes in MCL.
Methods: Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine (90 mg/m once daily; days 1 and 2) and rituximab (375 mg/m as a single dose; day 1) followed by rituximab maintenance in responding patients for 2 years.
Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.
Blood Adv
June 2025
Lymphoma Service, Alfred Hospital and Monash University, Melbourne, Victoria, Australia.
Bruton tyrosine kinase inhibitors (BTKis) have led to changes in the treatment algorithm for patients with high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), defined based on the presence of genetic mutations. Given the lack of head-to-head trials comparing next-generation BTKis used to treat high-risk R/R disease, a network meta-analysis (NMA) was performed to estimate their relative efficacy. High-risk populations were defined based on the prespecified definitions within each trial, including patients with del(17p) and/or TP53 mutations in the ALPINE (n = 150) and ASCEND (n = 86) trials, and del(17p)/del(11q) in the ELEVATE-RR (n = 533) trial.
View Article and Find Full Text PDFAcalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN.
Blood
April 2025
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States.
Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for treatment of chronic lymphocytic leukemia. We present results from ELEVATE-TN (NCT02475681) after median follow-up of 74.5 months.
View Article and Find Full Text PDF